CAR-T cell therapy research

This paper introduces cysteine-engineered CAR-T cells that target both conventional antigens and altered redox states in B cell lymphoma, reducing the risk of antigen escape.

This study characterizes CAR+ T-cell subsets and immune system dynamics in pediatric BCP-ALL patients treated with tisagenlecleucel, finding correlations between immune cell changes and cytokine release syndrome.

This paper introduces LogiCAR designer, a computational method using single-cell transcriptomics to identify logic-gated antigen combinations for CAR therapy, showing improved efficacy and safety compared to existing approaches.

This study shows that total body irradiation before CAR T cell infusion enhances their effectiveness against large B-cell lymphoma by improving cytotoxicity and survival outcomes.

This paper develops T-SenSER, a synthetic biosensor for T cells that enhances anti-tumor responses by sensing TME factors like VEGF and CSF1, showing improved efficacy in lung cancer and multiple myeloma models.

This study improves the in vivo efficacy of CD22-targeted CAR T cells by optimizing the balance between binding affinity and tonic signaling through rational redesign of the antigen binding domain.

This study identifies a Th1/Th17 imbalance driven by IFN{gamma} that causes cytokine release syndrome and neutropenia in CAR-T therapy, suggesting IFN{gamma} blockade as a potential treatment.

This study screens CAR-T designs in nonhuman primates and identifies MyD88-CD40 costimulatory domains as superior for proliferation, trafficking, and persistence.

This study identifies that the costimulatory domain of CD19-CAR-T cells influences resistance development in B-cell malignancies by affecting CD19 loss and antigen escape.

This paper proposes CAR-B cell therapy targeting anti-HLA Class I and II antibodies to reduce graft rejection and transfusion reactions by specifically neutralizing these antibodies and T cell responses.

The paper identifies combinatorial CAR signaling domains that enhance macrophage function and tumor clearance through pooled screening and single-cell analysis.

This study shows that varying CAR expression levels in T cells affects their activation, function, and transcriptional identity, with optimal CAR levels preventing exhaustion.

This paper develops a PDPN- and GD2-targeting CAR T cell blend to overcome glioblastoma heterogeneity, showing improved anti-tumor activity in organoids and increased survival in mice.

The paper shows that tumor-derived glucocorticoids increase ROR1 expression while suppressing T cell activity, and GC-resistant CAR-T cells can overcome this by preserving ROR1 expression in tumor cells.

This study shows that overexpressing MMP7 and SPP1 improves GD2.CART infiltration into solid tumors, leading to better tumor control and survival in a xenograft model.

This paper develops bi-specific CAR-iNKT cells targeting CD19 and CD133 for KMT2A-rearranged leukemia, showing superior efficacy over CAR-T in eradicating leptomeningeal disease and inducing remission.

This study compares viral and non-viral methods for CAR T cell engineering, finding that non-viral SB transposition alters T cell activation and co-inhibition markers, with CAR design and donor type influencing outcomes.

This paper develops a novel CAR-T cell therapy for glioblastoma that overcomes immunosuppression and improves persistence through a multi-armoured design.

This study develops a novel CAR-NK cell therapy using pluripotent stem cell-derived NK progenitors that persist in blood and eliminate minimal residual disease.

The antigen sensitivity of CAR-T cells can be tuned to match the sensitivity of TCR-T cells by varying the relative extracellular size of CAR/antigen and CD2/CD58 complexes.

This study uses phosphotyrosine proteomics to analyze CAR-T cells from patients and donors, finding heightened tyrosine phosphorylation and tonic signaling linked to therapeutic efficacy.

This study shows that boosting CAR-T cells with a VSV vaccine encoding the CAR-target leads to robust expansion but rapid contraction, while TCR-mediated boosting improves persistence and tumor eradication.

The paper develops a method to discover functional TCR-mimic CARs by combining library construction and screening, identifying effective CARs against specific tumor antigens.

This study generates TCR-null CAR T cells from iPSCs by controlling CAR signaling stages, resulting in naive-like cells with enhanced cytotoxicity.

This paper demonstrates the use of generative AI to design de novo binders for CAR-T cells targeting cancer antigens, showing comparable efficacy to traditional scFv-based CAR-T cells.

This study develops a PD-L1-targeting CAR T cell therapy, MC9999, which effectively eradicates glioblastoma and immunosuppressive cells in the tumor microenvironment through intracranial delivery.

This paper uses conditional optimal transport to model CAR T cell responses at the single-cell level and predict gene expression for unseen CAR variants.

This study develops in vivo engineered quadrivalent CAR-macrophages that break tumor barriers, remodel the TME, and overcome tumor heterogeneity through antigen spreading, achieving complete tumor regression.

This study uses temporal multi-modal single-cell profiling to show CAR-T cells interact dynamically with glioblastoma cells, including antigen-negative ones, and reduce their proliferation through IFN-gamma.